Table 1.

Patient demographicsa

PatientAge (yr)Months on DialysisCause of ESRFAtherosclerotic Vascular DiseaseDiagnosed IHDLVMI (g/m2.7)AngiogramAntianginal or BP-Lowering Drugs
18311MyelomaYN85.0N
27160UnknownYY (angina)52.1NFelodipine 10 mg once daily, atenolol 50 mg once daily
37233DiabetesNN55.3NValsartan 150 mg once daily
47119DiabetesYY (MI)96.7YbDiltiazem 90 mg once daily
54244SarcoidNN25.7N
66552DiabetesNN52.1Nc
7606APKDNN51.3N
8666DiabetesYN61.9NDiltiazem 300 mg, doxazosin 4 mg once daily, irbesartan 150 mg once daily
95517UnknownNN55.8NNifedipine 60 mg once daily, ramipril 10 mg once daily
106840Anti-GBMNN46.3N
Mean ± SD or n (%)65 ± 1129 ± 194 (40)2 (20)58.2 ± 201 (10)
  • a APKD, adult polycystic kidney disease; ESRF, end-stage renal failure; GBM, glomerular basement membrane; IHD, ischemic heart disease; LVMI, left ventricular mass index; MI, myocardial infarction.

  • b Angiogram result for patient 4: Diffuse three-vessel disease, not suitable for intervention.

  • c Patient 6 had had a dipyridamole stress test 12 mo before entering the study, which was negative.